FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1761532015> ?p ?o ?g. }

• W1761532015 abstract "Background/Purpose: Interferon alpha (IFNα) is associated with the severity and disease activity of SLE. Active immunization against IFNα induces polyclonal antibodies against all IFNα subtypes in vivo and prevents severe renal lupus disease in NZW/NZB SLE-prone mice. We evaluate IFNα-Kinoid in a first clinical study in SLE patients. Method: IFNα-Kinoid (IFNα-K, Neovacs SA, Paris, France) is an immunotherapeutic agent composed of recombinant human IFNα conjugated to KLH as a carrier protein, inactivated and adjuvanted with ISA-51 emulsion. Twenty-eight patients with mild to moderate, seropositive lupus (SLEDAI 4-10) were enrolled in a double-blind, placebo-controlled, phase 1-2, dose escalation study to evaluate the safety and the immunogenicity of four doses of IFNα-K (30, 60, 120 or 240 mg) administered intramuscularly on Days 0, 7 and 28 with an optional fourth dose on Day 84. Safety evaluation included recording of adverse events and monitoring of haematological and biochemical parameters. Immune responses were measured through titration of anti-IFNα and anti-KLH antibodies, and cellular lymphoproliferation assays. Clinical response was assessed by evaluation of BILAG, SLEDAI, PGA, SRI and titration of serum auto-antibodies, and of IFNα regulated chemokines. PBMC were harvested at several time-points and transcriptomic studies were performed on total RNA using Genechip HGU133 Plus 2.0 arrays. Results: The safety profile is very favourable. Few minor and transient local and systemic reactions have been observed following immunization. Only minor and transient infections were reported. Two lupus flares were reported as related serious adverse events, one in the active group in a patient who had spontaneously stopped glucocorticoid therapy after the first IFNα-K dose, the other in the placebo group. A dose-related anti-IFNα antibody response was measured in all immunized patients. Antibodies peak after the last dose and decline afterwards. Transcriptomic studies performed on baseline PBMC samples indicated that the patients cluster into two groups, characterized by the presence or absence of an IFNα signature. Patients with a positive signature have significantly higher dsDNA Ab titers and significantly lower C3 and C4 levels. In the patients with a baseline IFN signature, follow-up transcriptomic studies, performed as early as 38 days after the first IFNα-K injection, showed a significant down-regulation of the expression of IFN-induced genes in the IFNα-K group as compared to the placebo recipients, and, more generally, of SLE over-expressed genes as a whole. Conclusion: This is the first study to show positive immune and pharmacodynamic results with active immunotherapy against Interferon-α in the treatment of Systemic Lupus Erythematosus. These results are promising and further studies are planned in order to expand upon these observations" @default.
• W1761532015 created "2016-06-24" @default.
• W1761532015 creator A5027317477 @default.
• W1761532015 creator A5074039933 @default.
• W1761532015 date "2011-01-01" @default.
• W1761532015 modified "2023-09-27" @default.
• W1761532015 title "Active Immunization Against IFNα with IFN-Kinoid in SLE Patients Is Safe, Immunogenic and Induces Down-Regulation of IFN-Mediated Genes" @default.
• W1761532015 hasPublicationYear "2011" @default.
• W1761532015 type Work @default.
• W1761532015 sameAs 1761532015 @default.
• W1761532015 citedByCount "0" @default.
• W1761532015 crossrefType "journal-article" @default.
• W1761532015 hasAuthorship W1761532015A5027317477 @default.
• W1761532015 hasAuthorship W1761532015A5074039933 @default.
• W1761532015 hasConcept C126322002 @default.
• W1761532015 hasConcept C159654299 @default.
• W1761532015 hasConcept C163764329 @default.
• W1761532015 hasConcept C197934379 @default.
• W1761532015 hasConcept C203014093 @default.
• W1761532015 hasConcept C2776912625 @default.
• W1761532015 hasConcept C2779134260 @default.
• W1761532015 hasConcept C2780801004 @default.
• W1761532015 hasConcept C2780868878 @default.
• W1761532015 hasConcept C71924100 @default.
• W1761532015 hasConcept C8891405 @default.
• W1761532015 hasConcept C956191 @default.
• W1761532015 hasConceptScore W1761532015C126322002 @default.
• W1761532015 hasConceptScore W1761532015C159654299 @default.
• W1761532015 hasConceptScore W1761532015C163764329 @default.
• W1761532015 hasConceptScore W1761532015C197934379 @default.
• W1761532015 hasConceptScore W1761532015C203014093 @default.
• W1761532015 hasConceptScore W1761532015C2776912625 @default.
• W1761532015 hasConceptScore W1761532015C2779134260 @default.
• W1761532015 hasConceptScore W1761532015C2780801004 @default.
• W1761532015 hasConceptScore W1761532015C2780868878 @default.
• W1761532015 hasConceptScore W1761532015C71924100 @default.
• W1761532015 hasConceptScore W1761532015C8891405 @default.
• W1761532015 hasConceptScore W1761532015C956191 @default.
• W1761532015 hasLocation W17615320151 @default.
• W1761532015 hasOpenAccess W1761532015 @default.
• W1761532015 hasPrimaryLocation W17615320151 @default.
• W1761532015 hasRelatedWork W1574435394 @default.
• W1761532015 hasRelatedWork W193477023 @default.
• W1761532015 hasRelatedWork W1979200837 @default.
• W1761532015 hasRelatedWork W2004015587 @default.
• W1761532015 hasRelatedWork W2019739004 @default.
• W1761532015 hasRelatedWork W2061995362 @default.
• W1761532015 hasRelatedWork W2088778852 @default.
• W1761532015 hasRelatedWork W2107751463 @default.
• W1761532015 hasRelatedWork W2167736693 @default.
• W1761532015 hasRelatedWork W2280055230 @default.
• W1761532015 hasRelatedWork W2395968712 @default.
• W1761532015 hasRelatedWork W2398207142 @default.
• W1761532015 hasRelatedWork W2471060059 @default.
• W1761532015 hasRelatedWork W2532330411 @default.
• W1761532015 hasRelatedWork W2549716744 @default.
• W1761532015 hasRelatedWork W2728413137 @default.
• W1761532015 hasRelatedWork W2996290697 @default.
• W1761532015 hasRelatedWork W3013948009 @default.
• W1761532015 hasRelatedWork W3022308406 @default.
• W1761532015 hasRelatedWork W2775248277 @default.
• W1761532015 isParatext "false" @default.
• W1761532015 isRetracted "false" @default.
• W1761532015 magId "1761532015" @default.
• W1761532015 workType "article" @default.